Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
about
Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric DisordersFuture Directions for Pharmacotherapies for Treatment-resistant Bipolar DisorderBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewInflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Association of trauma exposure with proinflammatory activity: a transdiagnostic meta-analysisInflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials.An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar DisorderLC/QTOF profile and preliminary stability studies of an enriched flavonoid fraction of Cecropia pachystachya Trécul leaves with potential antidepressant-like activity.Mitigation of Inflammation-Induced Mood Dysregulation by Long-Chain Omega-3 Fatty AcidsPolyunsaturated fatty acids moderate the effect of poor sleep on depression riskRole of Long-Chain Omega-3 Fatty Acids in Psychiatric Practice.Low-grade inflammation predicts persistence of depressive symptomsCrosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis.Are medical comorbid conditions of bipolar disorder due to immune dysfunction?Studying longitudinal trajectories in animal models of psychiatric illness and their translation to the human conditionSystems Genomics Support for Immune and Inflammation Hypothesis of Depression.Effect of social interactions on hippocampal protein expression in animal dominant and submissive model of behavioral disorders.Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.Experimental drugs for bipolar psychosis.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.Antidepressant activity of fingolimod in mice.Do some anxiety disorders belong to the prodrome of bipolar disorder? A clinical study combining retrospective and prospective methods to analyse the relationship between anxiety disorder and bipolar disorder from the perspective of biorhythms.Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications.Vegans report less stress and anxiety than omnivores.Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial.Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls.Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms.
P2860
Q26767489-EB438AF0-5FE4-4A19-98DE-2BFFECA17A55Q26782989-E845E6A3-8ADA-480A-848C-048330FCF6BEQ26782993-64E07389-4CAA-4915-9FFF-F63EC78E1536Q33721019-6FB8CD3C-6AD2-477F-ACA1-882FA52A6FA4Q33990649-9C178F38-81C9-44AB-BAA3-1AA29B44A8BCQ34468355-5AF289B5-9553-41FF-A082-58EC14DADB1FQ35184044-9522D7C9-4CBB-4152-8915-FF0FD7DA7EDDQ36225284-C866E0A5-794B-43B2-8EB3-50B2D6593E71Q36332470-38B98CCF-9905-40C3-8B0D-C4D61B72C58DQ36391143-5D54BE04-5F45-4D95-9B76-1228B77B0FD5Q36642579-902DAB87-6C0A-4C14-812E-F1A9471BB3ACQ36773267-C3AB3134-F6D3-4CEC-86C4-BD9E47525498Q36789300-924EA530-8AA0-49DD-A3CA-B857CA628537Q36789308-11453EC8-8FF0-47A4-8BB5-D14B448E3D6AQ37089253-3460B0ED-D316-40DD-B861-FBB61FB06C27Q37629392-F5B64BC3-6F89-4F14-A5D6-755613AC0D99Q38378743-5EF298D9-6364-4D62-B912-03562903BE6AQ38567190-D5A76D30-8E4E-41D3-8509-C296A7B5CFE3Q38687599-F2D618ED-458F-41B8-8EFB-78F0E3F00DB7Q38692694-EF758DDA-B5F5-4430-BF6C-3524566926EAQ38779572-0EF7DC56-75E1-4267-BFE7-79E0241DC21FQ38995982-B2AE746D-C664-4F06-A5D2-081C312FD231Q39004668-3778FD50-0092-4261-AD99-7DE4A5E0780FQ39077270-6CCC7C16-0E26-411E-BA01-97FF26B7E338Q41359968-CE088160-EAC4-4A4F-B9ED-1C9AAAB6FCFCQ42633737-D5E4A97E-3860-4EBC-B19F-8875FAF20CE8Q47667767-02F7B8CD-7AAA-4F62-BB99-D0C3D6F828D8Q47786818-DEB31F08-0659-4950-A54F-A64C6D17C269Q48075396-81EBC35E-3470-4BA6-B2B6-A5141B84D5E0Q48204136-F6D66DDB-CE56-4AC2-B144-8F522BEFD5C5Q55070204-80E7DA2D-61ED-4DBA-8080-12FF779C9A17
P2860
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@ast
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@en
type
label
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@ast
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@en
prefLabel
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@ast
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@en
P2860
P356
P1476
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
@en
P2093
Francis E Lotrich
Robert K McNamara
P2860
P304
P356
10.1586/ERN.12.98
P577
2012-09-01T00:00:00Z